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A B S T R A C T
Purpose
In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of
thromboembolic events. In this randomized, open-label, multicenter trial, we compared aspirin
(ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for
preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens.
Patients and Methods
A total of 667 patients with previously untreated myeloma who received thalidomide-containing
regimens and had no clinical indication or contraindication for a specific antiplatelet or anticoagu-
lant therapy were randomly assigned to receive ASA (100 mg/d), WAR (1.25 mg/d), or LMWH
(enoxaparin 40 mg/d). A composite primary end point included serious thromboembolic events,
acute cardiovascular events, or sudden deaths during the first 6 months of treatment.
Results
Of 659 analyzed patients, 43 (6.5%) had serious thromboembolic events, acute cardiovascular
events, or sudden death during the first 6 months (6.4% in the ASA group, 8.2% in the WAR
group, and 5.0% in the LMWH group). Compared with LMWH, the absolute differences were
1.3% (95% CI, 3.0% to 5.7%; P  .544) in the ASA group and 3.2% (95% CI, 1.5% to
7.8%; P  .183) in the WAR group. The risk of thromboembolism was 1.38 times higher in
patients treated with thalidomide without bortezomib. Three major (0.5%) and 10 minor (1.5%)
bleeding episodes were recorded.
Conclusion
In patients with myeloma treated with thalidomide-based regimens, ASA and WAR showed similar
efficacy in reducing serious thromboembolic events, acute cardiovascular events, and sudden deaths
compared with LMWH, except in elderly patients where WAR showed less efficacy than LMWH.
J Clin Oncol 29:986-993. © 2011 by American Society of Clinical Oncology
INTRODUCTION
In patients with cancer, the incidence of venous
thrombosis is more than 7%1 but remains an
underdiagnosed and undertreated condition.2
Myeloma is associated with the highest risk
of thromboembolism.3
Cancer chemotherapy amplifies the prothrom-
botic effect of cancer cells and damages vessel
walls directly.4 The combination of melphalan,
prednisone, and thalidomide is now a standard of
care for the initial treatment of elderly patients
with myeloma.5-7 However, thalidomide signifi-
cantly increases the risk of thromboembolism.8-10
Small studies have evaluated the clinical bene-
fits of single-agent antithrombotic prophylaxis (as-
pirin [ASA], warfarin [WAR], or low molecular
weight heparin [LMWH]). Results of ASA and low-
dose WAR are conflicting.11-14 In a meta-analysis of
1,051 patients, the relative risk of thromboembolism
in patients treated with thalidomide and LMWH
was still 1.54 times higher than in patients not receiv-
ing thalidomide.10 The American Society of Clinical
Oncology guidelines recommend prophylaxis with
LMWH or adjusted-dose WAR in patients receiving
thalidomide.15 At present, no randomized study has
directly compared the clinical benefits of ASA,
WAR, and LMWH as thromboprophylaxis for
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patients with myeloma treated with thalidomide. This multicenter,
randomized, open-label study compared the efficacy and safety
of ASA or fixed low-dose WAR with LMWH in preventing throm-
boembolism in untreated patients with myeloma who received
thalidomide-containing regimens.
PATIENTS AND METHODS
Study Design and Treatment
This open-label, phase III, randomized study was conducted at 84 cen-
ters in Italy during May 2006 to January 2009 as a common substudy of two
simultaneous chemotherapy phase III trials using thalidomide-based regi-
mens in previously untreated patients with myeloma.16,17 The aim of this
study was to compare the effectiveness of ASA and WAR with LMWH as
antithrombotic prophylaxis. The study was approved by the institutional
review board at each of the participating centers. All patients gave written
informed consent before entering the study, which was performed in accor-
dance with the Declaration of Helsinki. The study was designed by the inves-
tigators, who were also responsible for the data collection. The data analysis
was performed by the investigators in conjunction with an independent statis-
tical office.
Patient Populations and Random Assignment
Previously untreated patients with myeloma who were enrolled onto one
of two studies16,17 were assessed for eligibility for the substudy. In one study,
patients age 65 years were randomly assigned to bortezomib (1.3 mg/m2 on
days 1, 4, 8, and 11), thalidomide (200 mg/d), and dexamethasone (320 mg) or
to thalidomide and dexamethasone in each 21-day cycle for three courses as
induction therapy before autologous transplantation.16 In the other study,
patients age 65 years were randomly assigned to bortezomib (1.3 mg/m2 on
days 1, 8, 15, and 22), melphalan (9 mg/m2 on days 1 to 4), prednisone (60
mg/m2 on days 1 to 4), and thalidomide (50 mg/d) for nine courses followed
by continuous therapy with bortezomib (1.3 mg/m2 every 15 days) and tha-
lidomide (50 mg/d) or to bortezomib, melphalan, and prednisone for nine
courses without any further continuous treatment.17 Patients randomly as-
signed to receive bortezomib, melphalan, and prednisone did not receive any
antithrombotic prophylaxis. Patients receiving thalidomide-based regimens
in both trials were eligible for the substudy. Exclusion criteria were allergy or
intolerance to study drugs, clear indication or contraindication for a specific
antiplatelet or anticoagulant therapy (eg, cardiac arrhythmia, cardiac isch-
emia, or previous history of arterial or venous thromboembolism), and active
bleeding or high risk of bleeding.
A simple random assignment sequence was generated by a centralized
computer. After registration in a centralized database through the Internet and
validation of eligibility, patients were randomly allocated to treatments using
an automated assignment procedure concealed to the investigators.
Study Interventions and Clinical Follow-Up
Patients receiving thalidomide-based regimens were randomly assigned
to receive one of the following: ASA 100 mg/d orally, WAR 1.25 mg/d orally, or
LMWH (enoxaparin) 40 mg/d subcutaneously. The prophylaxis was admin-
istered during the three cycles of induction therapy in the younger patients16
and during the first six cycles of induction therapy in the elderly patients.17 The
antithrombotic prophylaxis was discontinued in the event of deep vein throm-
bosis, pulmonary embolism, arterial thrombosis, acute cardiovascular event,
bleeding event, or platelet count 50,000/L. The international normalized
ratio (INR) was measured on days 1 and 21 of every cycle of chemotherapy. For
INR greater than 3, WAR was discontinued, and patients received adjusted
doses of WAR to maintain INR less than 3. Patients attended study visits every
3 weeks during the treatment period to assess the toxicity and efficacy of
treatment and subsequently at the physician’s discretion to evaluate the inci-
dence of thromboembolism in the absence of prophylaxis.
Outcome Measures
The primary end point was a composite measure defined as the
proportion of patients developing a first episode of objectively confirmed
symptomatic deep vein thrombosis, pulmonary embolism, arterial throm-
bosis, any acute cardiovascular event (acute myocardial infarction or
stroke), or sudden, otherwise unexplained death (presumed to be a result
of pulmonary embolism, acute myocardial infarction, or stroke) during
the first 6 months from random assignment. Secondary end points in-
cluded the comparison of each component of the composite primary end
point, long-term cumulative incidence of the primary end point, major
and minor bleeding events, and any toxicity that required interruption of
study prophylaxis. All adverse events were graded according to the Na-
tional Cancer Institute Common Terminology Criteria for Adverse Events
(version 3). The diagnostic procedures and definitions of the conditions
included in the composite end point are detailed in the Appendix (online
only). Major bleeding was defined as fatal bleeding, symptomatic bleeding
in a crucial area or organ, or bleeding causing a reduction in hemoglobin
concentration of  2 g/dL or necessitating transfusion of  two units of
whole blood or RBC cells.18 Minor bleeding was all other bleeding not
meeting the criteria for major bleeding.
Statistical Analysis
The statistical power and the minimum effect size detectable in this
trial was determined according to the sample size of the two predefined
chemotherapy phase III trials, which was 450 patients for the bortezomib,
thalidomide, and dexamethasone versus thalidomide and dexamethasone
trial16 and 500 patients for the bortezomib, melphalan, prednisone, and
thalidomide versus bortezomib, melphalan, and prednisone trial.17 Over-
all, we expected approximately 700 patients treated with thalidomide-
containing regimens to be randomly assigned, with a 1:1:1 allocation ratio
between the three prophylaxis regimens (approximately 230 patients per
group). The main planned comparisons were ASA versus LMWH and
WAR versus LMWH during the first 6 months from random assignment.
The expected rate of thromboembolic events in patients with newly diag-
nosed myeloma treated with thalidomide-containing regimens without
any prophylaxis is approximately 20% to 30%,10 and to be considered
effective, any prophylaxis should at least halve this risk. For each compar-
ison, a sample size of 230 patients per group reaches a statistical power
ranging from 53% to 86% to detect an absolute decrease of 5% to 7%,
respectively, between the groups, with   .05 (two tailed), assuming a
value of 10% for the composite primary end point in the LMWH group.
Because the two planned comparisons of the primary end point are true
independent hypotheses, we did not adjust for multiplicity.19 Two interim
analyses were planned at 15% and 45% of enrollment, using the O’Brien
and Fleming group sequential test design.20
The statistic test used to compare the difference between proportions was
the two-sided z test, with pooled variance. A subgroup analysis of the primary
composite end point was planned according to the three thalidomide-
containing regimens. To compare the incidence of the composite primary end
point through the entire follow-up, taking into account the competing risk of
dying from any other cause, the cumulative incidence, adjusted for competing
risks, was compared between groups with the Gray’s test. The hazard ratios
(HRs) with 95% CIs were estimated using the Fine and Gray’s proportional
hazard model.21,22 All efficacy and safety analyses were performed according
to the intent-to-treat principle and included all randomly assigned patients
who received at least one dose of the study drug. Times of observation were
censored on September 30, 2009. Time-to-event and continuous variables are
expressed as median with interquartile range (IQR). The post hoc analysis
concerning the association of thromboembolic events with potentially prog-
nostic baseline factors (age, performance status, presence or absence of comor-
bidities, high International Staging System stage, dose of corticosteroids, and
bortezomib association) was performed accounting for competing events.21,22
Interactions between treatment groups and covariates were assessed in
the model.
RESULTS
Of 991 patients assessed for eligibility, 734 had been randomly as-
signed to thalidomide-containing regimes and 257 had been assigned
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to thalidomide-free regimens (Fig 1). A total of 667 patients were
enrolled onto the substudy, of whom 659 received at least one dose of
the study treatment and were included in the efficacy and safety
analyses (ASA, n  220; WAR, n  220; LMWH, n  219; Fig 1).
Sixty-seven patients were not enrolled onto the study (Fig 1). Patient
characteristics were similar in all three groups (Table 1).
During the treatment period, symptomatic deep vein thrombo-
sis, pulmonary embolism, arterial thrombosis, any acute cardiovascu-
lar event, or sudden death (composite primary end point) occurred in
14 patients (6.4%) in the ASA group, 18 patients (8.2%) in the WAR
group, and 11 patients (5.0%) in the LMWH group (Table 2). The
absolute differences were1.3% (95% CI,3.0% to 5.7%;P .544)
between the ASA and LMWH groups and3.2% (95% CI,1.5% to
7.8%;P .183) between the WAR and LMWH groups (Table 3). The
risk of composite end point was similar in patients who received ASA
or LMWH and were treated with the different induction regimens
(Table 4). This risk was also similar in the younger patients who
received WAR or LMWH and were treated with thalidomide and
dexamethasone or bortezomib, thalidomide, and dexamethasone;
WAR was less effective than LMWH in the elderly patients treated
with bortezomib, melphalan, prednisone, and thalidomide (absolute
difference,11.3%; 95% CI, 3.4% to 19.2%; P .006; Table 4). The
incidence of thromboembolic events, acute cardiovascular events, and
sudden deaths was 5.4% in patients receiving thalidomide and bort-
ezomib and 7.2% in patients receiving thalidomide without bort-
ezomib (P  .60). In the thalidomide-bortezomib patients, the
absolute differences were1.5% (95% CI,3.9% to 7.1%; P .56)
between the ASA and LMWH groups and4.4% (95% CI,1.5% to
10.7%; P .13) between the WAR and LMWH groups. In the thalid-
omide patients, the absolute differences were1.0% (95% CI,7.9%
to 9.8%; P .81) between the ASA and LMWH groups and0.8%
(95% CI, 8.0% to 9.5%; P  .84) between the WAR and
LMWH groups.
The most frequent complications were thromboembolic events;
these occurred in 13 patients (5.9%) in the ASA group, 18 patients
(8.2%) in the WAR group, and seven patients (3.2%) in the LMWH
group in the first 6 months (Table 2). Symptomatic pulmonary em-
bolism occurred in eight patients in the first 6 months, including four
patients in the ASA group (one of whom died) and four patients in the
WAR group. No pulmonary embolism was reported in the LMWH
group. The absolute differences for serious thromboembolic events
were2.7% (95% CI,1.2% to 6.6%; P .173) between the ASA
Newly diagnosed myeloma patients
(N = 991)
)76 = n( dedulcxE
  Clear indication to anticoagulant therapy (n = 38)
  Clear indication to antiplatelet therapy (n = 26)
)2 = n( gnideelb fo ksir hgiH  
)1 = n( ekatsim naicinilC  
Assigned to ASA (n = 224)
  Did not receive ASA
    because not treated 
    with thalidomide (n = 4)
Assigned to WAR (n = 222)
  Did not receive WAR
    because not treated 
    with thalidomide (n = 2)
Assigned to LMWH (n = 221)
  Did not receive LMWH
    because not treated 
    with thalidomide (n = 2)
Analyzed (n = 220)
  Discontinued ASA (n = 35)
  Thrombosis or bleeding (n = 16)
  Stopping thalidomide (n = 19)
Analyzed (n = 220)
  Discontinued WAR (n = 46)
  Withdrawal of consent (n = 3)
  Thrombosis or bleeding (n = 15)
  Stopping thalidomide (n = 25)
Analyzed (n = 219)
  Discontinued LMWH (n = 26)
  Withdrawal of consent (n = 2)
  Thrombosis or bleeding (n = 8)
  Stopping thalidomide (n = 16)
≥ 65 years or < 65 years but not 
eligible for transplant
≤ 65 years and eligible
for transplant 
Thalidomide-based regimens
(Assessed for eligibility; n = 734) Not thalidomide-based regimen 
Randomly assigned
(n = 480)
Randomly assigned
(n = 667)
Randomly assigned
(n = 511)
VMP
(n = 257)
VMPT-VT
(n = 254)
TD
(n = 239)
VTD
(n = 241)
Fig 1. CONSORT diagram of patients in
the trial. VTD, bortezomib, thalidomide,
and dexamethasone; TD, thalidomide and
dexamethasone; VMPT-VT, bortezomib,
melphalan, prednisone, and thalidomide
followed by continuous therapy with bort-
ezomib and thalidomide; VMP, bortezomib,
melphalan, and prednisone; ASA, aspirin;
WAR, fixed low-dose warfarin; LMWH, low
molecular weight heparin.
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and LMWH groups and 5.0% (95% CI, 0.7% to 9.3%; P  .024)
between the WAR and LMWH groups (Table 3). The regression
model showed a tendency toward a higher risk of developing throm-
boembolic events in the following patients: patients older than age 60
years (HR, 1.75; 95% CI, 0.84 to 3.62); patients with more than two
comorbidities (HR, 1.43; 95% CI, 0.33 to 6.25); patients with a Kar-
nofsky performance status less than 70% (HR, 1.47; 95% CI, 0.70 to
3.09); patients not receiving bortezomib (HR, 1.38; 95% CI, 0.66 to
2.89); and patients receiving higher doses of dexamethasone (HR,
1.97; 95% CI, 0.72 to 5.39).
After a median follow-up of 24.9 months (IQR, 18.4 to 32.0
months), 58 patients (8.8%) experienced one of the events included in
the composite primary end point (Table 2). The cumulative propor-
tions of thromboembolic events, acute cardiovascular events, and
sudden deaths adjusted for competing risks at 18 months were 0.08
(95% CI, 0.05 to 0.12) in the ASA group, 0.10 (95% CI, 0.06 to 0.14) in
the WAR group, and 0.08 (95% CI, 0.04 to 0.11) in the LMWH group
(P .69; Fig 2). The HRs for ASA and WAR versus LMWH, adjusted
for competing risks, were 1.13 (95% CI, 0.59 to 2.17; P .716) and
1.31 (95% CI, 0.70 to 2.47; P .397), respectively. Any grade 3 or 4
thromboembolic events were reported in 17 patients (7.7%) in the
ASA group, 21 patients (9.5%) in the WAR group, and 11 patients
(5.0%) in the LMWH group (Table 2). No late pulmonary embolism
was observed. Most grade 3 to 4 thromboembolic events (78%) oc-
curred within the first 4 months; the median times to onset were 2.3
months (IQR, 1.4 to 3.1 months) in the ASA group, 2.3 months (IQR,
1.4 to 3.5 months) in the WAR group, and 4.5 months (IQR, 1.4 to
11.1 months) in the LMWH group. Overall, one patient died in the
Table 1. Baseline Demographics and Clinical Characteristics of Study Populations
Demographic or Clinical
Characteristic
ASA (n  220) WAR (n  220) LMWH (n  219)
No. of
Patients %
No. of
Patients %
No. of
Patients %
Age, years
Median 61 60 62
IQR 55-66 54-66 55-66
 55 54 25 61 28 55 25
56-65 103 47 100 45 102 47
66-75 52 24 43 20 50 23
 75 11 5 16 7 12 5
Male 117 53 115 52 130 59
MM treatment
TD 79 36 81 37 76 35
VTD 78 35 77 35 79 36
VMPT-VT 63 29 62 28 64 29
ISS
I 87 40 84 38 86 39
II 87 40 86 39 80 37
III 34 15 38 17 40 18
Data missing 12 5 12 5 13 6
Creatinine, mg/dL
Median 0.98 1.0 0.96
IQR 0.8-1.19 0.8-1.19 0.8-1.1
Glycemia, mg/dL
Median 94 92 93
IQR 86-102 85-102 86-102
Data missing 13 6 12 5 19 7
Karnofsky performance status
 70% 54 25 64 29 65 30
Data missing 8 4 12 5 8 4
Diabetes 10 5 9 4 8 4
Cardiovascular disease 35 16 48 22 38 17
Hypertension 29 13 44 20 33 15
Acute myocardial infarction 0 0 1 0.5 2 1
Heart failure 0 0 1 0.5 0 0
Arrhythmia 7 3 3 1 4 2
Other 0 0 0 0 1 0.5
Orthopedic disease 0 0 2 1 1 0.5
Dyslipidemia 4 2 7 3 4 2
Prior thromboembolism 2 1 2 1 1 0.5
 two comorbidities 7 3 10 5 4 2
Abbreviations: ASA, aspirin; WAR, fixed low-dose warfarin; LMWH, lowmolecular weight heparin; IQR, interquartile range; MM, multiple myeloma; TD, thalidomide
and dexamethasone; VTD, bortezomib, thalidomide, and dexamethasone; VMPT-VT, bortezomib, melphalan, prednisone, and thalidomide followed by continuous
therapy with bortezomib and thalidomide; ISS, International Staging System.
Système International conversion factors: to convert serum creatinine to mol/L, multiply by 88.4; to convert glucose to mmol/L, multiply by 0.0555.
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ASA group (pulmonary embolism), two patients died in the WAR
group (acute myocardial infarction and cardiac arrest), and one pa-
tient died in the LMWH group (cardiac arrest; Table 2).
The median durations of prophylaxis were 2.6 months (IQR,
2.1 to 4.0 months) in the ASA group, 2.4 months (IQR, 2.1 to 3.5
months) in the WAR group, and 2.6 months (IQR, 2.1 to 4.5
months) in the LMWH group. Thirty-five patients (16%) in the
ASA group, 46 patients (21%) in the WAR group, and 26 patients
(12%) in the LMWH group discontinued prophylaxis prema-
turely, mainly because of thromboembolic, cardiovascular, or
bleeding events, or because of thalidomide discontinuation for
adverse events or progressive disease (Fig 1). There were no statis-
tically or clinically significant differences among the three groups
in terms of the incidences of any adverse events during the treat-
ment or follow-up periods. Major bleeding occurred during the
first 6 months in three patients (1.4%) who received ASA but in no
patients who received either WAR or LMWH. Six patients (2.7%) in the
ASA group, one patient (0.5%) in the WAR group, and three patients
(1.4%) in the LMWH group had minor bleeding (Table 2).
DISCUSSION
Our findings showed that, in patients with myeloma treated with
thalidomide, the incidence of symptomatic deep vein thrombosis,
pulmonary embolism, arterial thrombosis, any acute cardiovascular
event, or sudden death was 6% during ASA, 8% during WAR, and 5%
during LMWH thromboprophylaxis, without statistically significant
Table 2. Incidence of Thromboembolic Events, Acute Cardiovascular Events, or Sudden Deaths and Bleeding by Treatment Group and Length of Follow-Up
Analysis
ASA (n  220) WAR (n  220) LMWH (n  219)
First 6 Months
Entire
Follow-Up First 6 Months
Entire
Follow-Up First 6 Months
Entire
Follow-Up
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
Efficacy analysis
Composite primary end point 14 6.4 19 8.6 18 8.2 22 10.0 11 5.0 17 7.8
Any grade 3 or 4 thromboembolic event 13 5.9 17 7.7 18 8.2 21 9.5 7 3.2 11 5.0
Deep vein thrombosis 8 3.6 12 5.5 14 6.4 17 7.7 6 2.7 10 4.6
Pulmonary embolism 4 1.8 4 1.8 4 1.8 4 1.8 0 0 0 0
Arterial thrombosis 1 0.5 1 0.5 0 0 0 0 1 0.5 1 0.5
Acute cardiovascular events 2 0.9 4 1.8 0 0 3 1.4 4 1.8 6 2.7
Acute myocardial infarction 0 0 2 0.9 0 0 1 0.5 3 1.4 4 1.8
Stroke 1 0.5 1 0.5 0 0 0 0 0 0 1 0.5
Sudden death 1 0.5 1 0.5 0 0 2 0.9 1 0.5 1 0.5
Safety analysis
Major bleeding 3 1.4 — — 0 0 — — 0 0 — —
GI 2 0.9 — — 0 0 — — 0 0 — —
Urinary tract 1 0.5 — — 0 0 — — 0 0 — —
Minor bleeding 6 2.7 — — 1 0.5 — — 3 1.4 — —
GI 1 0.5 — — 0 0 — — 1 0.5 — —
Urinary tract 2 0.9 — — 0 0 — — 0 0 — —
Nasal 1 0.5 — — 1 0.5 — — 1 0.5 — —
Skin 2 0.9 — — 0 0 — — 1 0.5 — —
Abbreviations: ASA, aspirin; WAR, fixed low-dose warfarin; LMWH, low molecular weight heparin.
The composite primary end point was the first episode of any objectively confirmed symptomatic deep vein thrombosis, pulmonary embolism, arterial thrombosis,
acute cardiovascular event (acute myocardial infarction or stroke), or sudden otherwise unexplained death (presumed to be a result of pulmonary embolism, acute
myocardial infarction, or stroke).
Table 3. Absolute Risk Difference of Thromboembolic Events, Acute Cardiovascular Events, or Sudden Deaths and Bleeding During the First 6 Months for
ASA and WAR Compared With LMWH
Event
ASA v LMWH WAR v LMWH
Absolute
Difference (%) 95% CI (%) P
Absolute
Difference (%) 95% CI (%) P
Composite primary end point 1.3 3.0 to 5.7 .544 3.2 1.5 to 7.8 .183
Any grade 3 or 4 thromboembolic event 2.7 1.2 to 6.6 .173 5.0 0.7 to 9.3 .024
Acute cardiovascular events 0.9 2.7 to 0.9 .313 1.4 2.9 to 0.2 .082
Major bleeding 1.4 0.2 to 2.9 .083 0.0 1.7 to 1.7 1.000
Minor bleeding 1.3 1.3 to 4 .316 0.9 2.7 to 0.9 .313
Abbreviations: ASA, aspirin; WAR, fixed low-dose warfarin; LMWH, low molecular weight heparin.
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differences between the ASA or WAR groups compared with the
LMWH group.
Without thromboprophylaxis, the incidence of thromboembolic
events has been reported to be 14% to 26% in patients with myeloma
receiving thalidomide plus dexamethasone23,24 and 10% to 20% in
patients receiving thalidomide plus melphalan.23 In the ASA group,
the incidence of thromboembolism was 6% over 6 months. In a
previous study, the rate of thromboembolism with ASA prophylaxis
was reported to be 11% to 18%.14 In our study, 8% of patients had
thromboembolic events during WAR therapy (6 months). In other
studies of patients taking thalidomide, dexamethasone, and fixed low-
dose WAR, the rate of thromboembolism has been reported to be 13%
to 25%.11,12,25 In our LMWH group, the incidence of thromboembo-
lism was 3% (6 months), which is consistent with other trials
including thalidomide plus LMWH (along with various combina-
tions of dexamethasone, prednisone, and melphalan), where the rate
of thromboembolism has been reported to be 0% to 9%.5,12,26 In our
study, the risk of thromboembolism was 1.38 times higher among
patients receiving thalidomide without bortezomib, which may
support the protective role of bortezomib against thromboembolism.
Bortezomib alone or in combination with dexamethasone or chemo-
therapy did not increase the risk of thromboembolism,27-29 whereas it
seems to confer protection when administered with thalidomide.16,30
The thalidomide analog lenalidomide is emerging as an interesting al-
ternative in the first-line therapy of myeloma. Most recent tri-
als have included thromboprophylaxis with ASA, which seemed to
be effective.31,32 The combination of lenalidomide-bortezomib-
dexamethasone with ASA prophylaxis showed promising results, with
a severe thromboembolism incidence of 5%.33
Prevention of thromboembolic complications has a central role
in the treatment of patients with cancer because the occurrence of
thromboembolism may cause chemotherapy discontinuation, in-
creases health expenditure, and requires anticoagulant treatment with
a higher risk of complications. To date, only results from small phase II
studies on single antithrombotic agents including ASA, WAR, or
LMWH are available.11-14,23,24,26 To our knowledge, our study is the
first randomized trial to question which antithrombotic prophylaxis
may be more effective. All three regimens were equally effective and
safe in patients with standard risk of thromboembolism. LMWH was
slightly superior to ASA and WAR, but some practical issues, such
as costs and feasibility of self-injection, should be considered. Both
ASA and WAR may be considered valid alternative options and are
less expensive, are administered orally, and do not require con-
stant monitoring.
In a recent meta-analysis, when thalidomide was used as mainte-
nance after autologous transplantation, the incidence of thromboem-
bolic events was 4% to 6%, and the risk of thromboembolism was 1.95
times higher than in patients who did not receive thalidomide.10 The
use of ASA for a longer period of time may reduce the risk of late
thromboembolism, and future studies should address this question.
The rates of pulmonary embolism and bleeding were higher
among patients receiving ASA than patients receiving LMWH. The
risk of bleeding in the ASA group was comparable with that seen in
other studies on thromboprophylaxis in patients with cancer.34,35 If
these increased risks are confirmed in a larger series of patients, they
may outweigh the practical advantages of ASA versus LMWH.
Patients at high risk of thromboembolic events, such as patients
with previous history of thromboembolism, severe cardiac disease,
uncontrolled diabetes, infections, immobilization, or surgery, were
not included in our analysis because they had a clear indication of
anticoagulant or antiplatelet therapy. This is a major limitation of the
Table 4. Absolute Risk Difference of Thromboembolic Events, Acute Cardiovascular Events, or Sudden Deaths During the First 6 Months of Treatment for ASA
and WAR Compared With LMWH, Stratified by Myeloma Treatment
Treatment
ASA v LMWH (heterogeneity test, P  .748) WAR v LMWH (heterogeneity test, P  .077)
Absolute
Difference (%) 95% CI (%) P
Absolute
Difference (%) 95% CI (%) P
TD 1.0 7.1 to 9.1 .805 0.8 7.1 to 8.8 .839
VTD 0.1 8.2 to 8.4 .982 1.1 9.1 to 6.9 .788
VMPT-VT 3.2 1.2 to 7.5 .151 11.3 3.4 to 19.2 .006
Abbreviations: ASA, aspirin; WAR, fixed low-dose warfarin; LMWH, low molecular weight heparin; TD, thalidomide and dexamethasone; VTD, bortezomib,
thalidomide, and dexamethasone; VMPT-VT, bortezomib, melphalan, prednisone, and thalidomide followed by continuous therapy with bortezomib and thalidomide.
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Fig 2. Cumulative incidence (proportion) of the primary composite end point,
adjusted for competing risks (other causes of death) by treatment group. The
follow-up endwas defined at 18months because no additional events occurred after
this time. The cumulative incidences of the primary composite end point (thrombo-
embolic events, acute cardiovascular events, or sudden deaths), adjusted for
competing risks, at 18 months were 0.08 (95% CI, 0.05 to 0.12) in the aspirin (ASA)
group, 0.10 (95% CI, 0.06 to 0.14) in the fixed low-dose warfarin (WAR) group, and
0.08 (95% CI, 0.04 to 0.11) in the low molecular weight heparin (LMWH) group
(Gray’s test P  .69).
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study. LMWH prophylaxis should remain mandatory in patients at
high risk of venous thromboembolism for at least the first 6 months of
therapy; thereafter, ASA may be considered to reduce the occurrence
of late thromboembolic events when long-term thalidomide therapy
is planned.
Further limitations of our study are the absence of a placebo
group and the open-label design. However, the inclusion of a placebo
arm would not have been ethical because all patients enrolled onto this
study were treated with thalidomide-containing regimens and could
have an increased risk of thromboembolic events.
To conclude, both ASA and WAR showed similar safety and
efficacy in reducing thromboembolic complications when compared
with LMWH in patients with myeloma treated with thalidomide-
based regimens. Antiangiogenic agents may inhibit the healing of
chemotherapy-induced endothelial injury, increasing the risk of
thromboembolism.36 Of note, defibrotide, which targets endothelial
cell damage, may have a protective effect against thromboembolism,
specifically induced by thalidomide.37,38 New and effective antithrom-
botic agents with reduced drug interactions and without the need for
constant monitoring could optimize patient care and eventually mod-
ify the indication for use and duration of thromboprophylaxis.
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